Oman vs Sur: Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati
Oman
99.0%
in 2025
Sur
0.0%
in 2025
Oman rank
1st
Sur rank
1st
Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati over time
- Oman
- Sur
How they compare
Oman currently reports 99.0% against 0.0% in Sur, a difference of 99.0%.
The two have swapped places 1 time across 18 shared years of data; in 2008 it was Sur ahead.
Oman ranks 1st and Sur ranks 1st of 194 countries.
Oman has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Oman | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 48.0% | 0.0% | 48.0% | Oman |
| 2010s | 98.8% | 0.0% | 98.8% | Oman |
| 2020s | 98.7% | 0.0% | 98.7% | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati, Oman or Sur?
- Oman, at 99.0% against 0.0% in Sur as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati between Oman and Sur?
- 99.0%, with Oman ahead.
- How many years of comparable data are there for Oman and Sur?
- 18 years are reported by both, from 2008 to 2025.
- How do Oman and Sur rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati?
- Oman ranks 1st and Sur ranks 1st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.